 |
|
|
| |
PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
David Bernstein1, Yan Luo2, Jacob Lalezari3, David Wyles4, William King5, Naoki Tsai6, Mitchell Davis7, Thomas Sepe8, Jeff rey Fessel9, Marti n King2, Thomas Podsadecki2, Curti s Cooper10
1North Shore University Hospital, Manhasset, New York, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Quest Clinical Research, San Francisco, California, United States; 4University of California San Diego, La Jolla, California, United States;
5Trial Management Associates, LLC, Wilmington, North Carolina, United States; 6Queens Medical Center, University of Hawaii, Honolulu, Hawaii, United States; 7Digesti ve Care, South Florida Center of Gastroenterology, Wellington, Florida, United States;
8University Gastroenterology, Providence, Rhode Island, United States; 9Kaiser Permanente, San Francisco, California, United States; 10Ott awa Hospital Research Insti tute, Ott awa, Ontario, Canada
|
| |
|
|
|
|
|
